ArticleChinese medicine2026
Esophageal epithelial cell-derived kynurenine drives Th17 inflammation in reflux esophagitis and is targeted by Xuanfu Daizhe decoction.
Article in Chinese medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundThe role of immunometabolic dysregulation in reflux esophagitis (RE), particularly the metabolic drivers of pathogenic T helper 17 (Th17) cell differentiation, is not fully understood. Although Xuanfu Daizhe Decoction (XDD) is a clinically effective Traditional Chinese Medicine (TCM) formula for RE, its potential to modulate these immunometabolic pathways remains unelucidated.
objectiveThis study aimed to investigate the mechanism by which tryptophan metabolic dysregulation in RE influences Th17 cell differentiation and to evaluate whether XDD exerts therapeutic effects by targeting this pathway.
methodsMetabolomic analysis was performed to assess alterations in the tryptophan metabolic pathway in serum from RE patients and RE rat models. Inflamed human esophageal epithelial cells (HEECs) model was established using acidified bile salts to observe kynurenine (KYN) secretion and its effect on Th17 differentiation. siRNA-mediated silencing of the aryl hydrocarbon receptor repressor (AHRR) was employed to clarify the role of AHRR in KYN-AhR-mediated Th17 differentiation. The interventional effects of XDD and its impact on the KYN-AHRR-AhR-Th17 axis were further examined in both cellular and rat models.
resultsMetabolomic profiling of clinical samples and RE rat models demonstrated significant dysregulation in the KYN pathway. Furthermore, we identified that inflamed HEECs induced high expression of IDO/TDO to elevate KYN secretion, which promoted Th17 cell differentiation. Mechanistically, KYN disrupted aryl hydrocarbon receptor (AhR) signaling via upregulation of its repressor, AHRR, thereby driving Th17 differentiation. Finally, we demonstrated that XDD treatment alleviated inflammation and tissue injury of RE by modulating the KYN-AHRR-AhR-Th17 axis.
conclusionThis study reveals a novel mechanism in RE whereby esophageal epithelial-derived KYN promotes Th17 differentiation via the AHRR-AhR signaling axis. Furthermore, XDD exerts therapeutic effects by modulating this immunometabolic pathway. These findings provide new insights into RE pathogenesis and experimental evidence supporting the application of XDD in immunometabolic disorders.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.